- $104.79m
- -$54.75m
- 41
- 46
- 93
- 63
Annual cashflow statement for HilleVax, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -2.1 | -102 | -160 | -124 | -147 |
| Depreciation | |||||
| Non-Cash Items | 0.779 | 83.8 | 101 | 11.8 | 49.9 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 0.052 | 11.3 | -3.15 | 22.8 | -14.6 |
| Change in Prepaid Expenses | |||||
| Change in Accrued Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Cash from Operating Activities | -1.27 | -7.29 | -62 | -86.8 | -109 |
| Capital Expenditures | 0 | -0.045 | -4.01 | -10.7 | -0.522 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 0 | -2.76 | -2.5 | -83.9 | 58.9 |
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | 0 | -2.81 | -6.51 | -94.6 | 58.4 |
| Financing Cash Flow Items | — | -0.789 | -19.7 | 0 | — |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 1.33 | 134 | 225 | 119 | -11.8 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 0.054 | 124 | 156 | -62.7 | -62.2 |